Review: Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes A new review article published in the journal Acta Pharmaceutica Sinica B summarizes advancements in drug delivery systems for three main glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are recommended for selected patients with obesity or type 2 diabetes, depending on indication, comorbidities, and treatment goals
doi: 10.1038/s41586-019-1426-6 15 DollSFreitasFPShahRAldrovandiMda SilvaMCIngoldIet al
Eating too close to bedtime can reduce the restorative quality of your sleep
In Phase 2 trials, retatrutide achieved up to 82% reduction in liver fat, a number that caught hepatologists by surprise
What about N-Acetyl Cysteine
Se han descrito interacciones con algunos tratamientos (por ejemplo, anticoagulantes) y se recomienda prudencia en epilepsia o patologa previa